非酒精性脂肪性肝病防治指南(2018年更新版)

中华医学会肝病学分会脂肪肝和酒精性肝病学组; 中国医师协会脂肪性肝病专家委员会

doi:10.3969/j.issn.1001-5256.2018.05.007

非酒精性脂肪性肝病防治指南(2018年更新版)

DOI: 10.3969/j.issn.1001-5256.2018.05.007

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1365
- HTML全文浏览量: 135
- PDF下载量: 2340
- 被引次数: 0
出版历程
- 出版日期: 2018-05-20

Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update

National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association,
Fatty Liver Expert Committee，Chinese Medical Doctor Association

摘要

摘要:
<正>非酒精性脂肪性肝病（non-alcoholic fatty liver disease,NAFLD）是一种与胰岛素抵抗（insulin resistance,IR）和遗传易感密切相关的代谢应激性肝损伤,疾病谱包括非酒精性肝脂肪变、非酒精性脂肪性肝炎（non-alcoholic steatohepatitis,NASH）、肝硬化和肝细胞癌（hepatocellular carcinoma,HCC）[1-2]。NAFLD不
- 脂肪肝 /
- 诊断 /
- 治疗 /
- 诊疗准则
- fatty liver /
- diagnosis /
- therapy /
- practice guideline

HTML全文

参考文献(66)

[1]RINELLA ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA, 2015, 313 (22) :2263-2273.

[2]DIEHL AM, DAY C.Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J].N Engl J Med, 2017, 377 (21) :2063-2073.

[3]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[4]FAN JG, KIM SU, WONG VW.New trends on obesity and NAFLD in Asia[J].J Hepatol, 2017, 67 (4) :862-873.

[5]WANG MM, WANG GS, SHEN F, et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J].Dig Dis Sci, 2014, 59 (10) :2571-2579.

[6]FAN JG, JIA JD, LI YM, et al.Guidelines for the diagnosis and management of nonalcoholic fatty liver disease:update 2010: (published in Chinese on Chinese Journal of Hepatology 2010;18:163-166) [J].J Dig Dis, 2011, 12 (1) :38-44.

[7]REVIEW TEAM, LABRECQUE DR, ABBAS Z, et al.World Gastroenterology Organisation global guideline:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2014, 48 (6) :467-473.

[8]WONG VW, CHAN WK, CHITTURI S, et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines2017-Part 1:definition, risk factors and assessment[J].J Gastroenterol Hepatol, 2018, 33 (1) :70-85.

[9]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2018, 67 (1) :328-357.

[10]European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity.Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.

[11]YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.

[12]ZHU JZ, ZHOU QY, WANG YM, et al.Prevalence of fatty liver disease and the economy in China:A systematic review[J].World J Gastroenterol, 2015, 21 (18) :5695-5706.

[13]WONG VW, WONG GL, YEUNG DK, et al.Incidence of nonalcoholic fatty liver disease in Hong Kong:a population study with paired proton-magnetic resonance spectroscopy[J].J Hepatol, 2015, 62 (1) :182-189.

[14]XU C, YU C, MA H, et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study[J].Am J Gastroenterol, 2013, 108 (8) :1299-1304.

[15]KWOK R, CHOI KC, WONG GL, et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut, 2016, 65 (8) :1359-1368.

[16]ZHANG RN, ZHENG RD, MI YQ, et al.APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases[J].Dig Dis Sci, 2016, 61 (8) :2284-2293.

[17]XU L, MA H, MIAO M, et al.Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease:a prospective case-control study[J].J Hepatol, 2012, 57 (5) :1153-1154.

[18]XU C, YU C, XU L, et al.High serum uric acid increases the risk for nonalcoholic Fatty liver disease:a prospective observational study[J].PLo S One, 2010, 5 (7) :e11578.

[19]MA H, XU C, XU L, et al.Independent association of Hb A1c and nonalcoholic fatty liver disease in an elderly Chinese population[J].BMC Gastroenterol, 2013, 13:3.

[20]XU C, WAN X, XU L, et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol, 2015, 62 (6) :1412-1419.

[21]DULAI PS, SINGH S, PATEL J, et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:systematic review and meta-analysis[J].Hepatology, 2017, 65 (5) :1557-1565.

[22]LEUNG JC, LOONG TC, WEI JL, et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology, 2017, 65 (1) :54-64.

[23]WANG Y, WANG B, SHEN F, et al.Body mass index and risk of primary liver cancer:a meta-analysis of prospective studies[J].Oncologist, 2012, 17 (11) :1461-1468.

[24]WONG VW, WONG GL, YEUNG JC, et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:a prospective cohort study[J].Hepatology, 2016, 63 (3) :754-763.

[25]BALLESTRI S, ZONA S, TARGHER G, et al.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome.Evidence from a systematic review and meta-analysis[J].J Gastroenterol Hepatol, 2016, 31 (5) :936-944.

[26]CHEN GY, CAO HX, LI F, et al.New-risk-scoring system including non-alcoholic fatty liver disease for predicting incident type2 diabetes in East China:Shanghai Baosteel Cohort[J].J Diabetes Investig, 2016, 7 (2) :206-211.

[27]WU S, WU F, DING Y, et al.Association of non-alcoholic fatty liver disease with major adverse cardiovascular events:A systematic review and meta-analysis[J].Sci Rep, 2016, 6:33386.

[28]TARGHER G, BYRNE CD, LONARDO A, et al.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J].J Hepatol, 2016, 65 (3) :589-600.

[29]WU R, HOU F, WANG X, et al.Nonalcoholic fatty liver disease and coronary artery calcification in a northern Chinese population:a cross sectional study[J].Sci Rep, 2017, 7 (1) :9933.

[30]MUSSO G, GAMBINO R, TABIBIAN JH, et al.Association of non-alcoholic fatty liver disease with chronic kidney disease:a systematic review and meta-analysis[J].PLo S Med, 2014, 11 (7) :e1001680.

[31]ZENG J, SUN C, SUN WL, et al.Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults at a health check-up[J].J Dig Dis, 2017, 18 (4) :229-236.

[32]DING W, FAN J, QIN J.Association between nonalcoholic fatty liver disease and colorectal adenoma:a systematic review and meta-analysis[J].Int J Clin Exp Med, 2015, 8 (1) :322-333.

[33]CHITTURI S, WONG VW, CHAN WK, et al.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines2017-Part 2:Management and special groups[J].J Gastroenterol Hepatol, 2018, 33 (1) :86-98.

[34]European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.

[35]XU L, LU W, LI P, et al.A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B[J].Dig Liver Dis, 2017, 49 (8) :910-917.

[36]SHEN F, ZHENG RD, MI YQ, et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol, 2014, 20 (16) :4702-4711.

[37]SHEN F, ZHENG RD, SHI JP, et al.Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J].Liver Int, 2015, 35 (11) :2392-2400.

[38]KARLAS T, PETROFF D, SASSO M, et al.Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J].J Hepatol, 2017, 66 (5) :1022-1030.

[39]SHEN F, ZHENG RD, MI YQ, et al.Value of a two-step approach with cytokeratin-18 and controlled attenuation parameter in noninvasive differential diagnosis of nonalcoholic steatohepatitis[J].Chin J Hepatol, 2016, 24 (6) :429-434. (in Chinese) 沈峰, 郑瑞丹, 宓余强, 等.细胞角蛋白-18联合受控衰减参数二步法无创鉴别非酒精性脂肪性肝炎的临床研究[J].中华肝脏病杂志, 2016, 24 (6) :429-434.

[40]BEDOSSA P, FLIP Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology, 2014, 60 (2) :565-575.

[41]XUN YH, FAN JG, ZANG GQ, et al.Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease[J].J Dig Dis, 2012, 13 (11) :588-595.

[42]PETTA S, WONG VW, CAMMC, et al.Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values[J].Hepatology, 2017, 65 (4) :1145-1155.

[43]ZENG J, SUN WL, CHEN GY, et al.Efficiency of Fibro Scan and Fibro Touch in liver stiffness measurement and fat quantification:a comparative analysis[J].Chin J Hepatol, 2016, 24 (9) :652-658. (in Chinese) 曾静, 孙婉璐, 陈光榆, 等.Fibro Touch与Fibro Scan肝脏硬度和脂肪定量检测效能的比较[J].中华肝脏病杂志, 2016, 24 (9) :652-658.

[44]SINGH S, MUIR AJ, DIETERICH DT, et al.American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases[J].Gastroenterology, 2017, 152 (6) :1544-1577.

[45]YU C, XU C, XU L, et al.Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease[J].J Hepatol, 2012, 56 (1) :241-247.

[46]NASCIMBENI F, PAIS R, BELLENTANI S, et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol, 2013, 59 (4) :859-871.

[47]ROMERO-GMEZ M, ZELBER-SAGI S, TRENELL M.Treatment of NAFLD with diet, physical activity and exercise[J].J Hepatol, 2017, 67 (4) :829-846.

[48]WONG VW, CHAN RS, WONG GL, et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:a randomized controlled trial[J].J Hepatol, 2013, 59 (3) :536-542.

[49]FAN JG, CAO HX.Role of diet and nutritional management in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 4) :81-87.

[50]ZHANG HJ, HE J, PAN LL, et al.Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease:a randomized clinical trial[J].JAMA Intern Med, 2016, 176 (8) :1074-1082.

[51]ZHANG HJ, PAN LL, MA ZM, et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:a 1-year follow-up study[J].Diabetes Obes Metab, 2017, 19 (2) :284-289.

[52]ARGO CK, PATRIE JT, LACKNER C, et al.Effects of n-3 fish oil on metabolic and histological parameters in NASH:a doubleblind, randomized, placebo-controlled tria[J].J Hepatol, 2015, 62 (1) :190-197.

[53]ATHYROS VG, TZIOMALOS K, GOSSIOS TD, et al.Safety and efficacyof long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study:a post-hoc analysis[J].Lancet, 2010, 376 (9756) :1916-1922.

[54]BRIL F, PORTILLO SANCHEZ P, LOMONACO R, et al.Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis:post hoc analysis of a randomized trial[J].J Clin Endocrinol Metab, 2017, 102 (8) :2950-2961.

[55]ARMSTRONG MJ, GAUNT P, AITHAL GP, et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) :a multicentre, double-blind, randomised, placebocontrolled phase 2 study[J].Lancet, 2016, 387 (10019) :679-690.

[56]CUSI K, ORSAK B, BRIL F, et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus:a randomized trial[J].Ann Intern Med, 2016, 165 (5) :305-315.

[57]BRITO JP, MONTORI VM, DAVIS AM.Metabolic surgery in the treatment algorithm for type 2 diabetes:a joint statement by international diabetes organizations[J].JAMA, 2017, 317 (6) :635-636.

[58]KLEBANOFF MJ, COREY KE, CHHATWAL J, et al.Bariatric surgery for nonalcoholic steatohepatitis:A clinical and cost-effectiveness analysis[J].Hepatology, 2017, 65 (4) :1156-1164.

[59] Chinese Society of Infectious Diseases, Chinese Medical Association, Expert Committeefor Prevenaon and Management of Liver Inflammation.Consensus statement by the expert committee for prevention and management of liver inflammation in China[J].Chin J Hepatol, 2014, 22 (2) :94-103. (in Chinese) 中华医学会感染病学分会, 肝脏炎症及其防治专家共识委员会.肝脏炎症及其防治专家共识[J].中华肝脏病杂志, 2014, 22 (2) :94-103.

[60]SANYAL AJ, CHALASANI N, KOWDLEY KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J].N Engl J Med, 2010, 362 (18) :1675-1685.

[61]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :a multicentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.

[62]HAN Y, SHI JP, MA AL, et al.Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose[J].Clin Drug Investig, 2014, 34 (1) :1-7.

[63]WAH KHEONG C, NIK MUSTAPHA NR, MAHADEVA S.A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol, 2017, 15 (12) :1940-1949.

[64]NEWSOME PN, ALLISON ME, ANDREWS PA, et al.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis[J].Gut, 2012, 61 (4) :484-500.

[65]PAIS R, BARRITT AS 4th, CALMUS Y, et al.NAFLD and liver transplantation:Current burden and expected challenges[J].J Hepatol, 2016, 65 (6) :1245-1257.

[66]AJMERA VH, TERRAULT NA, HARRISON SA.Is moderate alcohol use in nonalcoholic fatty liver disease good or bad?A critical review[J].Hepatology, 2017, 65 (6) :2090-2099.

施引文献

资源附件(0)

访问统计